181139-72-0Relevant articles and documents
Development of a biocatalytic process as an alternative to the (-)-DIP-Cl-mediated asymmetric reduction of a key intermediate of montelukast
Liang, Jack,Lalonde, James,Borup, Birthe,Mitchell, Vesna,Mundorff, Emily,Trinh, Na,Kochrekar,Cherat, Ramachandran Nair,Ganesh Pai
, p. 193 - 198 (2010)
A KetoREDuctase (KRED) engineered via directed evolution technologies catalyzed the asymmetric reduction of (F)-methyl 2-(3- (3-(2-(7-chloroquinolin- 2-yl)vinyl)phenyl)-3-oxopropyl)benzoate to the corresponding (S)-alcohol, a key intermediate in the synth
Method for synthesizing montrlukast sodium intermediate by means of series catalysis of graphene palladium cobalt
-
Paragraph 0007; 0013; 0014; 0015, (2017/08/30)
The invention relates to a technology for chemical synthesis of a medicine intermediate, in particular to a method for synthesizing a montrlukast sodium intermediate-[S-(E)]-2-[3-[3-[2-(7-chlorine-2-quinolyl)vinyl]phenyl]-3-hydroxy propyl]methyl benzoate by means of series catalysis of graphene palladium cobalt. The method adopts two steps of coupling and reducing and a one-pot series catalytic system; the obtained intermediate product does not need to be separated; the method is simple in operation, high in yield and good in chiral selectivity, thus being suitable for industrial production.
BIARYL DIPHOSPHINE LIGANDS, INTERMEDIATES OF THE SAME AND THEIR USE IN ASYMMETRIC CATALYSIS
-
Page/Page column 58, (2012/03/27)
The present disclosure relates to biaryl diphosphine ligands of the formula (B), processes for the production of the ligands and the use of the ligands in metal catalysts for asymmetric synthesis. The disclosure also relates to intermediates used for the production of the biaryl diphosphine ligand. (Formula (B))